関: embolization

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/08/05 13:06:52」(JST)

wiki en

This article is about a medical procedure.

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles (see embolization) coated with chemotherapeutic agents are injected selectively into an artery directly supplying a tumor.

History

In 1972, surgical ligation of the hepatic artery was first used to treat recurrent hepatic tumors followed by infusion of 5-fluorouracil into the portal vein. Due to the liver's dual blood supply from the hepatic artery and portal vein, interruption of the flow through the hepatic artery was demonstrated to be safe in patients. Tumor embolization eventually developed, blocking the vascular supply to a tumor by primarily endovascular approaches. The application of angiography with embolization followed, and the administration of chemotherapeutic agents with embolic particles evolved into transcatheter arterial chemoembolization.^[1]

Therapeutic applications

Transcatheter arterial chemoembolization has most widely been applied to hepatocellular carcinoma (HCC) for patients who are not eligible for surgery.^[2] TACE has been shown to increase survival in patients with intermediate HCC by BCLC criteria. It has also been used as an alternative to surgery for resectable early stage HCC and in patients with regional recurrence of the tumor after previous resection. TACE may also be used to downstage HCC in patients who exceed the Milan criteria for liver transplantation. Other treated malignancies include neuroendocrine tumors, ocular melanoma, cholangiocarcinoma, and sarcoma. Transcatheter arterial chemoembolization plays a palliative role in patients with metastatic colon carcinoma. There is a possible benefit for liver-dominant metastases from other primary malignancies.

Procedure

TACE is an interventional radiology procedure performed in the angiography suite. The procedure involves gaining percutaneous transarterial access by the Seldinger technique to the hepatic artery with an arterial sheath, usually by puncturing the common femoral artery in the right groin and passing a catheter guided by a wire through the abdominal aorta, through the celiac trunk and common hepatic artery, and finally into the branch of the proper hepatic artery supplying the tumor. The interventional radiologist then performs an selective angiogram of the celiac trunk and possibly the superior mesenteric artery to identify the branches of the hepatic artery supplying the tumor(s) and threads smaller, more selective catheters into these branches. This is done to maximize the amount of the chemotherapeutic dose that is directed to the tumor and minimize the amount of the chemotherapeutic agent that could damage the normal liver tissue.

When a blood vessel supplying tumor has been selected, alternating aliquots of the chemotherapy dose and of embolic particles, or particles containing the chemotherapy agent, are injected through the catheter. The total chemotherapeutic dose may be given in one vessel's distribution, or it may be divided among several vessels supplying the tumors.

The physician removes the catheter and access sheath, applying pressure to the entry site to prevent bleeding. The patient must lie stationary for several hours after the procedure to allow the punctured artery to heal. The patient will often be kept overnight for observation and will likely be discharged the following day. The procedure is normally followed up with a CT scan several weeks later to check the response of the tumor to the procedure.

Agents

Lipiodol – mixed with chemotherapeutic agents (Lipiodol is nonocclusive, combined with Gelfoam, Ivalon, or other particles)

Drug eluting particles – slow, sustained release of loaded drug locally with embolic effect leading to tumor ischemia

- Polyvinyl alcohol microspheres - loaded with doxorubicin

- Superabsorbent polymer microspheres - loaded with doxorubicin

- Gelatin microspheres – loaded with cisplatin

Principles

TACE derives its beneficial effect by two primary mechanisms.^[3] Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumor's blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, which is typically the dose limiting factor. This effect is potentiated by the fact that the chemotherapeutic drug is not washed out from the tumor vascular bed by blood flow after embolization. Effectively, this results in a higher concentration of drug to be in contact with the tumor for a longer period of time.^[4]

Park et al. conceptualized carcinogenesis of HCC as a multistep process involving parenchymal arterialization, sinusoidal capillarization, and development of unpaired arteries (a vital component of tumor angiogenesis). All these events lead to a gradual shift in tumor blood supply from portal to arterial circulation. This concept has been validated using dynamic imaging modalities by various investigators. Sigurdson et al. demonstrated that when an agent was infused via the hepatic artery, intratumoral concentrations were ten times greater compared to when agents were administered through the portal vein. Hence, arterial treatment targets the tumor while normal liver is relatively spared. Embolization induces ischemic necrosis of tumor causing a failure of the transmembrane pump, resulting in a greater absorption of agents by the tumor cells. Tissue concentration of agents within the tumor is greater than 40 times that of the surrounding normal liver.

Adverse Effects

As with any interventional procedure, there is a small risk of hemorrhage and/or damage to blood vessels. Pseudoaneurysm can develop at the site of puncture in the femoral artery. During this procedure contrast media is utilized, to which patients may develop an allergic reaction. Symptomatic hypothyroidism may result from the high retained iodine load of the contrast. Off-target delivery of embolic agents such as reflux into healthy surrounding tissue is a potential side effect that may cause complications such as ulceration of the gut or cholecystitis. Specialized techniques and devices may decrease the risk. TACE induces tumor necrosis in more than 50% of patients; the resulting necrosis releases cytokines and other inflammatory mediators into the bloodstream. A self-limiting postembolization syndrome of pain, fever, and malaise may occur due to hepatocyte and tumor necrosis.^[5] Transaminases may elevate 100-fold, and a leukemoid reaction is not uncommon.

Intrahepatic abscess (treated by percutaneous drainage) and gallbladder ischemia are extremely rare. Rising bilirubin is a warning sign of irreversible hepatic necrosis, generally occurring in the setting of cirrhosis. In an effort to reduce the likelihood of significant hepatic toxicity, chemoembolization should be restricted to a single lobe or major branch of the hepatic artery at one time. The patient may be brought back after 1 month, once toxicities and abnormal chemistries have resolved, to complete the procedure in the opposite lobe. Retreatment of new lesions may be necessary, if patients fulfill the original eligibility criteria.

References

^ Guan YS, He Q, Wang MQ (2012). "Transcatheter arterial chemoembolization: history for more than 30 years". ISRN Gastroenterol.
^ Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D (2006). "Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies". J Vasc Interv Radiol 17 (2): 217–23. doi:10.1097/01.rvi.0000196277.76812.a3.
^ Miraglia R, Pietrosi G, Maruzzelli L, et al. (2007). "Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma". World J Gastroenterol 13 (21): 2952–5.
^ Rammohan A, Sathyanesan J, Ramaswami S, et al. (2012). "Embolization of liver tumors: Past, present and future". World J Radiol 4 (9): 405–12. doi:10.4329/wjr.v4.i9.405.
^ Stuart K (2003). "Chemoembolization in the management of liver tumors". Oncologist 8 (5): 425–37. doi:10.1634/theoncologist.8-5-425.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肝細胞癌に対する治療法の概要 overview of treatment approaches for hepatocellular carcinoma
2. 局所性肝細胞癌に対する非外科的治療：動脈塞栓術、放射線療法、および放射線塞栓療法 nonsurgical therapies for localized hepatocellular carcinoma transarterial embolization radiotherapy and radioembolization
3. 大腸癌の肝転移に対する非外科的局所治療戦略 nonsurgical local treatment strategies for colorectal cancer liver metastases
4. 傍神経節腫および褐色細胞腫：悪性疾患のマネージメント paraganglioma and pheochromocytoma management of malignant disease
5. 切除可能な肝細胞癌のマネージメント：予後、術前補助化学療法と補助化学療法の役割、および治療後サーベイランス management of potentially resectable hepatocellular carcinoma prognosis role of neoadjuvant and adjuvant therapy and posttreatment surveillance

English Journal

Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.

Chen J1, White SB2, Harris KR3, Li W4, Yap JW5, Kim DH6, Lewandowski RJ6, Shea LD7, Larson AC8.
Biomaterials.Biomaterials.2015 Aug;61:299-306. doi: 10.1016/j.biomaterials.2015.05.010. Epub 2015 May 15.
Transcatheter arterial embolization and chemoembolization are standard locoregional therapies for hepatocellular carcinoma (HCC). However, these can result in tumor hypoxia, thus promoting tumor angiogenesis. The anti-angiogenic agent sorafenib is hypothesized to improve outcomes; however, oral admi
PMID 26022791

Doxorubicin-loaded poly(lactic-co-glycolic acid) microspheres prepared using the solid-in-oil-in-water method for the transarterial chemoembolization of a liver tumor.

Choi JW1, Park JH2, Baek SY1, Kim DD2, Kim HC3, Cho HJ4.
Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2015 Aug 1;132:305-12. doi: 10.1016/j.colsurfb.2015.05.037. Epub 2015 May 27.
Doxorubicin (DOX)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres (MSs) were fabricated using the solid-in-oil-in-water (S/O/W) emulsification method for transarterial chemoembolization (TACE) of a liver tumor. DOX-loaded PLGA MSs with a mean diameter of 26μm and a spherical shape were pre
PMID 26057730

Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern.

Zhang X1, Li C, Wen T, Yan L, Li B, Yang J, Wang W, Xu M, Lu W, Jiang L.
European journal of gastroenterology & hepatology.Eur J Gastroenterol Hepatol.2015 Aug;27(8):933-40. doi: 10.1097/MEG.0000000000000383.
OBJECTIVE: The aim of this study was to investigate appropriate treatment strategies for recurrent intrahepatic hepatocellular carcinoma (HCC) in patients who fulfilled the Milan criteria at primary hepatectomy.PATIENTS AND METHODS: A total of 124 patients who underwent curative-intent resection of
PMID 25933127

Japanese Journal

症例報告肝細胞癌に対する肝動脈化学塞栓療法施行直後に腫瘍破裂を来した一例

福井悠美,佐伯一成,花園忠相 [他],田邉規和,浦田洋平,日髙勲,寺井崇二,坂井田功
山口医学 = Yamaguchi medical journal 64(1), 35-40, 2015-02
… 肝細胞癌(HCC;hepatocellular carcinoma)の自然破裂はしばしば遭遇する病態である.しかし,肝動脈化学塞栓療法(TACE;transcatheter arterial chemoembolization)施行直後に破裂を来した症例の報告は比較的まれであり,今回,HCCに対しTACE施行直後に破裂を来した一例を経験したので報告する.患者は73歳男性,背景肝は慢性肝障害(非B非C)であり,20XX年5月に肝S7のHCCに対して,開胸開腹S7亜区域切除術を施行した.翌年5月,肝両葉にHCCの再発を認め,リピオ …
NAID 120005601214

急速に進行した膵Solid Pseudopapillary Neoplasmの1例

山口厚,飯尾澄夫,壺井章克,山下賢,森豪,保田和毅,山口敏紀,桑井寿雄,河野博孝,倉岡和矢,谷山清己,有廣光司,高野弘嗣
膵臓 30(2), 233-242, 2015
症例は，63歳男性．2010年5月，急激な上腹部痛にて救急搬送された．CTにて，膵体部に50mm大の低濃度腫瘤を認めた．MRCP，EUS，USにて，腫瘍内に出血とのう胞成分を認めた．肝転移巣から腫瘍生検を行い，H.E染色にてSolid Pseudopapillary Neoplasm（SPN）が疑われた．免疫染色にてCD10強陽性，Vimentin陽性，Chromogranin A陰性などからSP …
NAID 130005068120

原発不明神経内分泌癌の肝転移の1例

森廣俊昭,青木秀樹,金谷信彦,武田正,須井健太,重安邦俊,荒田尚,勝田浩,田中屋宏爾,竹内仁司
日本消化器外科学会雑誌 48(2), 94-101, 2015
　肝腫瘍として見つかり，肝切除術後に原発不明神経内分泌癌（neuroendocrine carcinoma；以下，NECと略記）と診断された症例を経験したので報告する．症例は67歳の男性で，肝S6に20 mm大の腫瘤と肝門部リンパ節腫大が確認された．腫瘍が増大傾向にあり，PET-CTでもFDG集積が確認されたため，肝S6亜区域切除および肝門部リンパ節郭清を行った．切除標本でNECと診断され，肝S6 …
NAID 130004908170